re: Ann: Mix and Go at Emerging Technology Co...
A royalties biased deal would highlight Management's expectation of market penetration IMHO. However eBio would have attempt to negotiate for whats best for their books too, but on a long term deal mutual benefit is the go. I'm not putting too much weight on the details of this particular deal. Look so many things, for and against, could be read into whatever the deal outcome. e.g. On the same terms it could be argued - Is it a deal at premium for market signal, OR a deal at discount for early adoption? Whatever it is, it is only the forth deal - the measure will be the sum of the basket of deals Management can secure.
NB: I see the latest preso notes Life Technology's TO of eBioscience. Acknowledgement and/or highlight?
ADO Price at posting:
8.3¢ Sentiment: Hold Disclosure: Held
